NCT00451880 - Study of XL281 in Adults With Solid Tumors | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

CancerNon-small-cell Lung CancerColorectal CancerPapillary Thyroid CancerMelanoma

Interventions

DRUG

XL281

Gelatin capsules supplied as 5-, 25-, and 100-mg strengths

DRUG

famotidine

single dose, supplied as 20-mg or 40-mg tablets

Trial Locations (6)

Memorial Sloan Kettering Cancer Center, New York

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sarah Cannon Research Institute, Nashville

Barbara Ann Karmanos Cancer Institute, Detroit

Mary Crowley Cancer Research Center, Dallas

Premiere Oncology of Arizona, Scottsdale